Risk factors for choroidal neovascularization and vision loss in the fellow eye study of CNVPT

Retina

Volumn 23, Issue 3, 2003, Pages 307-314

  Prenner, Jonathan L ^a   Rosenblatt, Brett J ^b   Tolentino, Michael J ^c,d   Ying, Gui Shuang ^c   Javornik, Noreen B ^c   Maguire, Maureen G ^c   Ho, Allen C ^b  

^a ASSOCIATED RETINAL CONSULTANTS   (United States)

^b WILLS EYE HOSPITAL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d NONE   (United States)

Author keywords

Choroidal neovascularization; Drusen; Macular degeneration; Risk factors

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL OBSERVATION; CLINICAL RESEARCH; CLINICAL TRIAL; DRUSEN; EVALUATION; EYE DISEASE; FEMALE; FLUORESCENCE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; LASER SURGERY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATHOPHYSIOLOGY; RETICULAR PSEUDODRUSEN; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; SUBRETINAL NEOVASCULARIZATION; SYMPATHETIC OPHTHALMIA; VISUAL IMPAIRMENT;

EID: 0038756782     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-200306000-00004     Document Type: Article

References (14)

1. Klein R, Klein BEK, Jensen SC, Meuer SM. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1997;104:7-21.
2. The Choroidal Neovascularization Prevention Trial Research Group. Choroidal neovascularization in the Choroidal Neovasculatization Prevention Trial. Ophthalmology 1998;105:1364-1372.
3. Macula Photocoagulation Study Group. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol 1997;115:741-747.
4. Vingerling JR, Hofman A, Grobbee DE, de Jong PT. Age-related macular degeneration and smoking. The Rotterdam Study. Arch Ophthalmol 1996;114:1193.
5. The Eye Disease Case-Control Study Group. Risk factors for neovascular age-related macular degeneration. Arch Ophthalmol 1997;110:1701-1708.
6. Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: age-related eye disease study report number 3. Ophthalmology 2000;107:2224-2232.
7. Pauleikhoff D, Zuels S, Shaeraidah GS, et al. Correlation between biochemical composition and fluorescein binding of deposits in Bruch's membrane. Ophthalmology 1992; 99:1548-1553.
8. Pauleikhoff D, Chen JC, Chisholm IH, Bird AC. Choroidal perfusion abnormality with age-related Bruch's membrane change. Am J Ophthalmol 1990;109:211-217.
9. Arnold JJ, Sarks SH, Killingsworth MC, Sarks JP. Reticular pseudodrusen. A risk factor in age-related maculopathy. Retina 1995;15:183-191.
10. The Choroidal Neovascularization Prevention Trial Research Group. Laser treatment in eyes with large drusen. Short term effects seen in a pilot randomized clinical trial. Ophthalmology 1998;105:11-23.
11. International ARM Epidemiology Study Group. An international classification and grading system for age-related maculopathy and age-related macular degeneration. Surv Ophthalmol 1995;39:367-374.
12. Macula Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration: guidelines for evaluation and treatment in the Macular Photocoagulation Study. Arch Ophthalmol 1991;109:1242-1257.
13. Klein R, Davis MD, Magli YL, et al. The Wisconsin age-related maculopathy grading system. Ophthalmology 1991; 98:1128-1134.
14. Choroidal Neovascularization Prevention Trial Research Group. Laser treatment in fellow eyes with large drusen: updated findings from a pilot randomized clinical trial. Ophthalmology 2003;110(5):971-8.